Zandra Klippel

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Meletios Α. Dimopoulos, Hang Quach, María‐Victoria Mateos et al. · The Lancet · 2020 · 415 citations

Hematological Malignancy, Medicine, Hematology +9

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Façon, Jae Hoon Lee, Philippe Moreau et al. · Blood · 2019 · 125 citations · Full text

Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies

Yanli Li, Zandra Klippel, Xiaolong Shih et al. · Supportive Care in Cancer · 2016 · 46 citations

Hematological Malignancy, Medicine, Malignant Blood Disorder +8

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, Hang Quach, María‐Victoria Mateos et al. · Blood · 2019 · 43 citations

Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC

Zandra Klippel, Jeffrey Chou, Andrea Towlerton et al. · Gene Therapy · 2014 · 38 citations · Full text

Autoimmune Disease, Ny-eso-1-specific T-cell Therapy, Medicine +10